Antiretroviral drug trials
Van Rompay, K.K.; Marthas, M.L.
Science 276(5318): 1482-1484
1997
ISSN/ISBN: 0036-8075 PMID: 9190679 Document Number: 483536
Document emailed within 1 workday
Related Documents
Bellamy, N.; Carette, S.; Ford, P.M.; Kean, W.F.; le Riche, N.G.; Lussier, A.; Wells, G.A.; Campbell, J. 1992: Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials--results of a consensus development (Delphi) exercise Journal of Rheumatology 19(3): 451-457Baesi, K.; Ravanshad, M.; Ghanbarisafari, M.; Saberfar, E.; Seyedalinaghi, S.; Volk, J.E. 2014: Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran Journal of Medical Virology 86(7): 1093-1098
Rajesh, L.; Karunaianantham, R.; Narayanan, P.R.; Swaminathan, S. 2009: Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients Aids Research and Human Retroviruses 25(11): 1179-1185
Hamers, R.L.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Conradie, F.; Botes, M.E.; Wellington, M.; Osibogun, A.; Sigaloff, K.C.E.; Nankya, I.; Schuurman, R.; Wit, F.W.; Stevens, W.S.; van Vugt, Mèle.; de Wit, T.F.Rinke.; Mandaliya, K.; Abdallah, S.; Jao, I.; Dolan, M.; Schuurman, R.; Wensing, A.M.; Hamers, R.L.; Sigaloff, K.C.E.; Straatsma, E.; Wit, F.W.; van Vugt, M.; Lange, J.M.; Rinke de Wit, T.F.; Osibogun, A.; Akanmu, S.; Botes, M.E.; Conradie, F.; Ive, P.; Sanne, I.; Wallis, C.L.; Letsoalo, E.; Stevens, W.S.; Hardman, M.; Kityo, C.; Namayanja, G.; Nakatudde, L.; Nankya, I.; Kiconco, M.; Abwola, M.; Mugyenyi, P.; Ndembi, N.; Lyagoba, F.; Kaleebu 2011: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study Lancet. Infectious Diseases 11(10): 750-759
Newman, H.; Breunig, L.; van Zyl, G.; Stich, A.; Preiser, W. 2014: A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 60(4): 387-391
Bellamy, N.; Anastassiades, T.P.; Buchanan, W.W.; Davis, P.; Lee, P.; McCain, G.A.; Wells, G.A.; Campbell, J. 1991: Rheumatoid arthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials of antirheumatic drugs Journal of Rheumatology 18(12): 1901-1907
Lange, J.M.; Richman, D.D. 1996: Antiretroviral therapy and clinical trials: what now? Antiviral Therapy 1(2): 69-70
Bazin, C.; Régnier, B. 1992: Antiretroviral treatments and their therapeutical trials La Revue du Praticien 42(2): 148-153
Ayala, R.C.; Arya, V.; Younis, I.R. 2016: Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives Journal of Clinical Pharmacology 56(5): 541-547
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Kigen, G.; Kimaiyo, S.; Nyandiko, W.; Faragher, B.; Sang, E.; Jakait, B.; Owen, A.; Back, D.; Gibbons, S.; Seden, K.; Khoo, S.H.; Nyandiko, W.; Wools-Kaloustian, K.; Kimaiyo, S.; Braitstein, P.; Sang, E.; Jakait, B.; Pastakia, S. 2011: Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort Plos one 6(2): E16800
Ssemwanga, D.; Ndembi, N.; Lyagoba, F.; Magambo, B.; Kapaata, A.; Bukenya, J.; Lubega, G.W.; Bertagnolio, S.; Vandepitte, J.; Grosskurth, H.; Kaleebu, P. 2012: Transmitted antiretroviral drug resistance among drug-naive female sex workers with recent infection in Kampala, Uganda Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54(Suppl 4): S339-S342
Weidle, P.J.; Malamba, S.; Mwebaze, R.; Sozi, C.; Rukundo, G.; Downing, R.; Hanson, D.; Ochola, D.; Mugyenyi, P.; Mermin, J.; Samb, B.; Lackritz, E. 2002: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance Lancet 360(9326): 34-40
Aghokeng, A.F.; Kouanfack, C.; Laurent, C.; Ebong, E.; Atem-Tambe, A.; Butel, C.; Montavon, C.; Mpoudi-Ngole, E.; Delaporte, E.; Peeters, M. 2011: Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients Aids 25(17): 2183-2188
Choi, J-Yeon.; Kim, E-Jin.; Park, Y.Keun.; Lee, J-Shil.; Kim, S.Soon. 2008: National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naive patients with HIV/AIDS in South Korea: 1999-2005 Journal of Acquired Immune Deficiency Syndromes 49(3): 237-242
Hamers, R.L.; Schuurman, R.; Sigaloff, K.C.E.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Ive, P.; Botes, M.E.; Wellington, M.; Osibogun, A.; Wit, F.W.; van Vugt, M.èl.; Stevens, W.S.; de Wit, T.F.R. 2012: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study LANCET. Infectious Diseases 12(4): 307-317
Gleiter, C.H.; Bieck, P.R. 1991: Clinical drug trials. 1: the 4 phases of clinical trials Fortschritte der Medizin 109(5): 136-137
Jaillon, P. 1985: Drug trials in man Revue de l'Infirmiere 35(11): 23-27
Skene, L. 1989: Ethics and drug trials Medical Journal of Australia 150(1): 55